

Soluble TIM3 and its ligands Galectin-9 and CEACAM1 are in disequilibrium during Alcohol-related Liver Disease and promote impairment of anti-bacterial immunity.

Antonio Riva^{1,2,*}, Elena Palma^{1,2}, Dhruti Devshi^{1,2}, Douglas Corrigan^{1,2,3}, Huyen Adams^{1,2,4}, Nigel Heaton⁵, Krishna Menon⁵, Melissa Preziosi⁵, Ane Zamalloa⁵, Rosa Miquel⁶, Jennifer M Ryan⁷, Gavin Wright³, Sarah Fairclough³, Alexander Evans⁴, Debbie Shawcross², Robert Schierwagen⁸, Sabine Klein⁸, Frank E Uchner⁸, Michael Praktikj⁹, Krum Katzarov¹⁰, Tanya Hadzhiolova¹⁰, Slava Pavlova¹⁰, Marieta Simonova¹⁰, Jonel Trebicka^{8,11}, Roger Williams^{1,2}, Shilpa Chokshi^{1,2,*}

1 Institute of Hepatology (Foundation for Liver Research), London, UK

2 Faculty of Life Sciences and Medicine (King's College London), London, UK

3 Department of Gastroenterology, Basildon University Hospital, Basildon, UK

4 Department of Gastroenterology, Royal Berkshire Hospital, Reading, UK

5 Institute of Liver Studies (King's College London), London, UK

6 Liver Histopathology Laboratory, Institute of Liver Studies, King's College Hospital

7 Gastrointestinal and Liver Services, Royal Free Hospital, London, UK

8 Translational Hepatology, Department of Internal Medicine I, University Clinic Frankfurt, Frankfurt, Germany

9 Department of Internal Medicine I, University of Bonn, Bonn, Germany

10 Department of Gastroenterology, Hepatobiliary surgery and Transplantology, Military Medical Academy, Sofia, Bulgaria


11 European Foundation for the Study of Chronic Liver Failure, EF-CLIF, Barcelona, Spain

* Corresponding authors


Short title: Soluble immune checkpoints in ALD

Keywords: TIM3; immune checkpoint; alcohol; biomarker




Supplementary Figures and Tables




Supplementary figure 1




Supplementary figure 2




Supplementary figure 3




Supplementary figure 4




Supplementary figure 5



Supplementary figure 6



Supplementary figure 7



Supplementary figure 8

FACS panel for mTIM3 assessment						
Marker	Color/Format	Clone	Laser/Ex Filter	Em Filter	Company	Catalog
CD14	BUV395	MphiP9	UV	355	BD Biosciences	563561
CD16	BUV737	3G8	UV	379/28	BD Biosciences	612786
CD3	Brilliant Violet 510	UCHT1	V	740/35	BD Biosciences	300448
CD8a	SuperBright 600	SK1	V	405	Thermo Fisher Scientific	63-0087-42
CD56	Brilliant Violet 711	HCD56	V	405	Biologend	318336
CD19	SuperBright 780	SI25C1	V	405	Thermo Fisher Scientific	78-0198-42
TIM3	FITC	F38-2E2	B	488	Thermo Fisher Scientific	11-3109-42
CD4	PE-Dazzle 594	OKT4	YG	530/30	Biologend	317448
Ghost Dye Red 710	Ghost Dye Red 710	N/A	R	610/20	Tonbo Biosciences (Cambridge Bioscience)	13-0871-T500
				730/45		
FACS panel for rhTIM3-Ig cultures						
Marker	Color/Format	Clone	Laser/Ex Filter	Em Filter	Company	Catalog
CD3	Brilliant Violet 510	UCHT1	V	405	Biologend	300448
IFNg	Alexa Fluor 488	4S.B3	B	488	Biologend	502515
IL-10	PE	JES3-9D7	B	488	Biologend	501404
CD8a	PerCP-eFluor710	SK1	B	488	eBioscience	46-0087-42
IL-17	Alexa Fluor 647	SCPL1362	R	633	BD	560437
CD4	APC-eFluor780	OKT4	R	633	eBioscience	47-0048-42
				780/60		
FACS panel for anti-Galectin-9 antibody cultures						
Marker	Color/Format	Clone	Laser/Ex Filter	Em Filter	Company	Catalog
CD14	BUV395	MphiP9	UV	355	BD Biosciences	563561
CD3	Brilliant Violet 510	UCHT1	V	405	Biologend	300448
CD8a	SuperBright 600	SK1	V	405	Thermo Fisher Scientific	63-0087-42
IL-17	Brilliant Violet 650	BL168	V	405	Biologend	512304
IL-10	FITC	4S.B3	B	488	Thermo Fisher Scientific	BMS131-2FI
IFNg	PE	25723	YG	561	R&D	IC285P-100
CD4	PE-Dazzle 594	OKT4	YG	561	Biologend	317448
Ghost Dye Red 710	Ghost Dye Red 710	N/A	R	610/20	Tonbo Biosciences (Cambridge Bioscience)	13-0871-T500
				730/45		

Supplementary table 1

	Stats	HC	ARC	SAH
sTIM3	#5	2057.57 (1663.47 – 2179.89)	3912.93 (2756.22 – 4730.43)	4522.30 (3589.62 – 4726.76)
sCD80	#4	441.21 (337.02 – 470.16)	1172.48 (649.75 – 1938.85)	1493.36 (1009.56 – 2422.43)
sLAG3	#1	51.67 (46.64 – 76.94)	124.67 (66.15 – 196.88)	90.58 (73.67 – 107.46)
sHVEM	#1	141.37 (101.72 – 388.40)	82.18 (56.78 – 141.83)	52.45 (38.73 – 87.48)
sPDL1	(#1)	4.59 (3.96 – 10.22)	10.74 (8.59 – 16.58)	10.22 (7.17 – 11.27)
sCD137		89.18 (60.29 – 121.59)	130.65 (95.05 – 204.27)	126.13 (93.88 – 153.04)
sCD27		1874.70 (1504.41 – 2362.32)	2764.04 (1468.85 – 4952.98)	2774.13 (2631.39 – 4898.27)
sPDL2		1642.96 (1231.25 – 1829.19)	2217.21 (1534.49 – 3303.72)	2800.48 (1857.30 – 3321.46)
sIDO		24.43 (20.84 – 43.22)	34.89 (30.63 – 68.67)	38.26 (26.65 – 47.29)
sGITR		13.68 (7.93 – 77.36)	83.18 (44.02 – 145.72)	36.78 (25.22 – 158.82)
sBTLA		1202.58 (980.29 – 1583.70)	1491.51 (1034.11 – 2129.54)	1118.88 (952.71 – 1555.23)
sCD28		144.26 (126.08 – 233.04)	212.55 (144.26 – 322.07)	156.28 (138.23 – 197.86)
sCD152		44.23 (37.94 – 62.00)	51.36 (43.33 – 65.31)	45.12 (38.84 – 55.80)
sPD1		59.13 (41.16 – 108.18)	89.11 (47.57 – 163.74)	66.00 (48.52 – 105.04)

All measurements are in pg/mL. Data expressed as median (IQR).
= significant difference between HC/ARC/SAH (Benjamini-Hochberg (BH) adjusted Kruskal-Wallis test)
1 symbol: BHq≤0.05 / 2 symbols: BHq≤0.01 / 3 symbols: BHq≤0.005 / 4 symbols: BHq≤0.001 / 5 symbols: BHq≤0.0005
(symbol) = non-significant trend, (p≤0.05) but BH-adjusted q>0.05

Supplementary table 2

Correlations		Log10_sBTLA	Log10_sCD137	Log10_sCD152	Log10_sCD27	Log10_sCD28	Log10_sCD80	Log10_sgITR	Log10_sHVEM	Log10_siDO	Log10_sLAG3	Log10_sPD1	Log10_sPD1.1	Log10_sPD1.2	Log10_sTIM3
p-value		Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)
Log10_sBTLA		1.14E-06	1.14E-06	1.18E-06	6.74E-02	2.67E-06	1.45E-01	1.10E-05	8.82E-08	3.71E-02	6.66E-03	7.01E-07	2.29E-04	3.16E-04	2.62E-03
Log10_sCD137		1.18E-06	1.86E-10	1.86E-10	1.78E-01	5.03E-11	1.62E-01	1.84E-06	1.61E-05	5.66E-03	3.85E-03	1.28E-06	3.53E-07	3.28E-03	1.04E-02
Log10_sCD152		6.74E-02	3.65E-02	4.02E-16	3.65E-02	4.02E-16	4.92E-02	2.27E-07	9.73E-08	4.97E-03	2.68E-03	1.51E-07	2.50E-09	9.43E-05	3.84E-04
Log10_sCD27		2.67E-06	1.78E-01	2.23E-01	2.23E-01	2.23E-01	7.21E-01	2.74E-01	1.32E-01	5.40E-01	7.67E-01	2.81E-01	1.26E-02	6.69E-02	5.63E-05
Log10_sCD28		2.47E-06	5.03E-11	4.02E-16	2.23E-01	2.23E-01	1.97E-01	4.29E-09	1.12E-07	7.30E-04	4.45E-04	1.95E-08	1.23E-10	3.83E-03	2.81E-03
Log10_sCD80		1.45E-01	1.62E-01	4.92E-02	7.21E-01	1.97E-01	2.27E-01	2.27E-01	7.56E-01	9.20E-02	2.91E-02	5.33E-02	1.62E-01	1.47E-03	2.74E-02
Log10_sgITR		1.10E-05	1.84E-06	2.27E-07	2.74E-01	4.29E-09	2.27E-01	3.87E-07	3.87E-07	2.60E-03	1.89E-02	2.29E-15	2.16E-06	6.48E-02	2.07E-02
Log10_sHVEM		8.82E-08	1.61E-05	9.73E-08	1.32E-01	1.12E-07	7.56E-01	1.27E-03	2.60E-03	6.68E-02	7.99E-02	1.28E-06	5.30E-04	1.81E-02	5.20E-02
Log10_siDO		3.71E-02	5.66E-03	4.97E-03	5.40E-01	7.30E-04	9.20E-02	1.27E-03	2.60E-03	6.68E-02	6.68E-02	3.44E-03	3.15E-03	3.29E-03	3.99E-02
Log10_sLAG3		6.66E-03	3.85E-03	2.68E-03	7.67E-01	4.45E-04	5.33E-02	2.29E-15	1.26E-06	3.44E-03	5.49E-03	1.04E-05	1.04E-05	2.16E-02	2.06E-02
Log10_sPD1		2.29E-04	3.53E-07	1.51E-07	2.81E-01	1.23E-10	1.62E-01	2.16E-06	5.30E-04	6.68E-02	3.15E-03	2.16E-02	1.13E-02	1.13E-02	4.48E-04
Log10_sPD1.1		3.16E-04	3.28E-03	9.43E-05	6.69E-02	3.83E-03	1.47E-03	6.48E-02	1.81E-02	6.88E-02	3.29E-03	2.16E-02	1.13E-02	1.13E-02	4.48E-04
Log10_sPD1.2		2.62E-03	1.04E-02	3.84E-04	5.63E-05	2.81E-03	2.74E-02	2.07E-02	5.20E-02	1.25E-01	3.99E-02	2.06E-02	4.48E-04	3.51E-05	3.51E-05
Log10_sTIM3															
corr. coeff.		Log10_sBTLA	Log10_sCD137	Log10_sCD152	Log10_sCD27	Log10_sCD28	Log10_sCD80	Log10_sgITR	Log10_sHVEM	Log10_siDO	Log10_sLAG3	Log10_sPD1	Log10_sPD1.1	Log10_sPD1.2	Log10_sTIM3
Log10_sBTLA		Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation	Pearson Correlation
Log10_sCD137		1.000	0.719	0.718	0.313	0.701	0.252	0.669	0.765	0.354	0.450	0.728	0.584	0.574	0.493
Log10_sCD152		0.719	1.000	0.844	0.233	0.857	0.242	0.709	0.660	0.458	0.476	0.717	0.741	0.483	0.428
Log10_sCD27		0.718	0.844	1.000	0.355	0.932	0.335	0.749	0.763	0.464	0.492	0.756	0.815	0.612	0.567
Log10_sCD28		0.313	0.233	0.355	1.000	0.233	-0.063	0.190	0.211	-0.107	-0.052	0.188	0.418	0.313	0.627
Log10_sCD80		0.701	0.857	0.932	0.211	1.000	0.932	0.808	0.761	0.544	0.562	0.788	0.848	0.476	0.490
Log10_sgITR		0.252	0.242	0.335	-0.063	0.223	1.000	0.210	0.054	0.289	0.369	0.329	0.242	0.517	0.373
Log10_sHVEM		0.669	0.709	0.749	0.190	0.808	0.210	1.000	0.740	0.523	0.395	0.924	0.706	0.316	0.390
Log10_siDO		0.765	0.660	0.763	0.211	0.761	0.054	0.740	1.000	0.493	0.300	0.717	0.556	0.397	0.331
Log10_sLAG3		0.450	0.458	0.464	-0.107	0.544	0.289	0.523	0.493	1.000	0.313	0.481	0.451	0.311	0.264
Log10_sPD1		0.428	0.476	0.492	-0.052	0.562	0.369	0.395	0.300	0.313	1.000	0.459	0.485	0.483	0.349
Log10_sPD1.1		0.728	0.717	0.756	0.188	0.788	0.329	0.924	0.717	0.481	0.459	1.000	0.485	0.387	0.390
Log10_sPD1.2		0.574	0.483	0.815	0.418	0.848	0.517	0.706	0.566	0.485	0.485	0.485	1.000	0.671	0.562
Log10_sTIM3		0.493	0.428	0.567	0.627	0.490	0.373	0.316	0.331	0.311	0.349	0.387	0.562	0.640	1.000

Supplementary table 3

Correlations		Log10_sBTLA	Log10_sCD137	Log10_sCD152	Log10_sCD27	Log10_sCD28	Log10_sCD80	Log10_sgITR	Log10_shVEM	Log10_sIDO	Log10_sLAG3	Log10_sPD1	Log10_sPDL1	Log10_sPDL2	Log10_sTIM3
p-value	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)	Sig. (2-tailed)
Log10_sBTLA	6.29E-05														
Log10_sCD137	3.65E-08	6.29E-05													9.43E-01
Log10_sCD152	7.53E-07	3.65E-08	6.29E-05												8.90E-01
Log10_sCD27	8.66E-01	7.53E-07	3.65E-08	6.29E-05											9.89E-01
Log10_sCD28	9.38E-10	7.53E-07	3.65E-08	6.29E-05	8.66E-01										7.31E-04
Log10_sCD80	1.83E-05	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10									9.95E-01
Log10_sgITR	4.28E-05	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05								9.77E-01
Log10_shVEM	1.09E-06	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05	4.28E-05							6.83E-01
Log10_sIDO	1.34E-05	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05	4.28E-05	1.09E-06						8.14E-01
Log10_sLAG3	2.76E-03	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05	4.28E-05	1.09E-06	1.34E-05					9.06E-01
Log10_sPD1	9.31E-05	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05	4.28E-05	1.09E-06	1.34E-05	2.76E-03				7.06E-01
Log10_sPDL1	1.91E-02	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05	4.28E-05	1.09E-06	1.34E-05	2.76E-03	9.31E-05			
Log10_sPDL2	1.36E-02	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05	4.28E-05	1.09E-06	1.34E-05	2.76E-03	9.31E-05	1.91E-02		
Log10_sTIM3	7.06E-01	7.53E-07	3.65E-08	6.29E-05	8.66E-01	9.38E-10	1.83E-05	4.28E-05	1.09E-06	1.34E-05	2.76E-03	9.31E-05	1.91E-02	1.36E-02	
corr. coeff.															
Log10_sBTLA	1.000														
Log10_sCD137	0.883	1.000													
Log10_sCD152	0.971	0.949	1.000												
Log10_sCD27	-0.052	-0.249	-0.142	1.000											
Log10_sCD28	0.985	0.926	0.996	-0.117	1.000										
Log10_sCD80	0.907	0.950	0.996	-0.117	1.000										
Log10_sgITR	0.891	0.851	0.920	-0.094	0.939	1.000									
Log10_shVEM	0.945	0.851	0.920	-0.094	0.939	1.000	0.806								
Log10_sIDO	0.839	0.917	0.935	-0.151	0.931	0.883	0.883	1.000							
Log10_sLAG3	0.839	0.917	0.935	-0.151	0.931	0.883	0.883	1.000	0.945						
Log10_sPD1	0.949	0.907	0.935	-0.128	0.954	0.932	0.932	1.000	0.945	0.901					
Log10_sPDL1	0.722	0.590	0.696	-0.251	0.705	0.591	0.591	1.000	0.945	0.901	0.839				
Log10_sPDL2	0.653	0.824	0.783	-0.251	0.740	0.826	0.826	1.000	0.945	0.901	0.839	0.839			
Log10_sTIM3	0.022	-0.042	0.004	0.813	0.002	-0.009	-0.009	0.231	-0.125	0.073	0.093	0.623	0.116	1.000	

Supplementary table 4

Coefficients (a,b) Model	Collinearity Statistics	
	VIF	Tolerance (1 / VIF)
(Intercept)	---	---
Log10_sBTLA	6.068	0.165
Log10_sCD137	6.848	0.146
Log10_sCD152	29.904	0.033
Log10_sCD27	4.419	0.226
Log10_sCD28	34.009	0.029
Log10_sCD80	3.128	0.320
Log10_sGITR	6.595	0.152
Log10_sHVEM	9.329	0.107
Log10_sIDO	2.559	0.391
Log10_sLAG3	3.013	0.332
Log10_sPD1	6.372	0.157
Log10_sPDL1	6.879	0.145
Log10_sPDL2	4.059	0.246
Log10_sTIM3	5.670	0.176

a. Dependent Variable: Group (HC / ARC / SAH)
b. VIF > 5 indicates the presence of multicollinearity (the higher the stronger)

[illegible]

Supplementary table 7

Supplementary figure legends.

Supplementary figure 1. Pro-inflammatory and anti-inflammatory cytokines in ALD patients.

(A) Significance plot summarising cytokine measurements in HC, ARC and SAH; cytokine measurements: standardised z-scores; significance: $-\log_{10}(\text{p-value})$; red continuous line: BH significance threshold; red dotted line: $p=0.05$; black bars: significantly different cytokines; grey bars: non-significant cytokines. Additionally, individual boxplots for cytokine measurements in HC, ARC and SAH; KWp: raw Kruskal-Wallis p-value; BHq: FDR-adjusted q-value; p: significant multiple comparisons with Dunn's correction. Boxplots (median, IQR, $\pm$ Tukey's whiskers/outliers) ordered by decreasing statistical significance.

Supplementary figure 2. Soluble-CR levels in whole blood from four blood compartments in ARC patients. No differences in soluble-CR levels in plasma obtained from four anatomical compartments in 20 ARC patients undergoing TIPS; measurements are matched by subject (Friedman's paired test).

Supplementary figure 3. Soluble-CRs are not released from the liver upon acute ethanol (EtOH) exposure. (A) Lack of soluble-CR production in PCLS treated with ethanol 250 mM for 24 hours (Mann-Whitney test. Each dot represents one slice; each colour represents one subject). Boxplots (median, IQR, $\pm$ full range). (B) Lack of cellular toxicity by EtOH, measured as total cell death or % apoptotic cell death by cytokeratin (CK)18 fragments ELISA. Each dot represents one slice; red line: median. (C) Haematoxylin and eosin staining of PCLS, showing maintenance of tissue architecture after EtOH treatment.

Supplementary figure 4. Soluble-CR levels in whole blood upon acute bacterial challenge. Unchanged soluble-CR levels in E. coli-pulsed whole blood (Mixed Model analysis, with significant fixed effect by subject group but not by stimulation).

Supplementary figure 5. Representative FACS gating. Representative FACS plots showing the sequential gating for the measurement of membrane-TIM3 expression on T-cells (CD4/CD8), NK-cells (CD56hi/CD56lo), B-cells and monocytes.

Supplementary figure 6. Expression of membrane-TIM3 on immune subsets and modulation by E. coli. (A) membrane-TIM3 % at baseline (day 1, unstimulated) on T-cells (CD4/CD8), NK-cells (CD56hi/CD56lo), B-cells and monocytes (Kruskal-Wallis test with Dunn's multiple comparison correction). (B) Modulation of membrane-TIM3 % during a 7-day E. coli-stimulated culture; assessments performed at days 1-4-7; data expressed as E. coli fold ratio vs unstimulated medium (Mixed Model analysis, with fixed effect comparisons by group). Boxplots: median, IQR, $\pm$ Tukey's whiskers/outliers.

Supplementary figure legends.

Supplementary figure 7. Plasma soluble-TIM3 correlates with membrane-TIM3 expression on T-cells and NK-cells, and with their response to E. coli stimulation. Plasma soluble-TIM3 levels are positively correlated with basal (unstimulated) membrane-TIM3 expression in T-cells and NK-cells. However, plasma soluble-TIM3 levels correlate negatively with membrane-TIM3 upregulation response during antibacterial challenge. Each dot represents one subject; red continuous line: linear regression line; red dotted lines: 95% CI bands for the linear regression line. Correlations evaluated by Spearman's correlation analysis.

Supplementary figure 8. Galectin-9 blockade is not sufficient to rescue anti-bacterial responses in SAH patients. Specific blocking of Galectin-9 in PBMC cultures from SAH patients (n=4) with a neutralising monoclonal antibody was not sufficient to rescue the production of E. coli-stimulated antibacterial T-cell IFN γ (A) or anti-inflammatory T-cell IL-10 (C). Its effects on the production of pro-inflammatory IL-17A by CD8 T cells (B) and anti-inflammatory IL-10 by monocytes (D) were marginal and almost non-significant. Shading identifies different culture conditions as specified along each graph's x-axis. Boxplots: median, IQR, $\pm$ Tukey's whiskers/outliers.

Supplementary table legends.

Supplementary table 1. Antibodies used for flow cytometry. All the markers are indicated with their respective fluorochrome, antibody clone, physical excitation/emission lines and manufacturer's details.

Supplementary table 2. Soluble-CR levels measured in HC, ARC and SAH plasma.

Supplementary table 3. Intercorrelation matrix of soluble-CRs in ALD patients. The table lists the p-values and correlation coefficients calculated by Pearson's correlation analysis.

Supplementary table 4. Intercorrelation matrix of soluble-CRs in healthy controls. The table lists the p-values and correlation coefficients calculated by Pearson's correlation analysis.

Supplementary table 5. Variance Inflation factor analysis for plasma soluble-CR measurements in ALD patients and HC. The table lists the 'variance inflation factor' for each soluble-CR, a measurement of multivariate collinearity/correlation. Values above 5 indicate the presence of collinearity.

Supplementary table 6. Correlation analysis for plasma soluble-CR levels, cytokine measurements, clinical parameters and surrogate markers of bacterial translocation (D-lactate and soluble-CD163) in ALD patients. The table lists the p-values and correlation coefficients calculated by Pearson's correlation analysis.

Supplementary table 7. Lack of correlation between plasma soluble-CR levels and pro-/anti-inflammatory cytokines in healthy controls. The table lists the p-values and correlation coefficients calculated by Pearson's correlation analysis.